The effect of the in vivo treatment of peripheral blood leukocytes (PBL) from patients with prostatic cancer with the controversial drug amygdalin (AMG), commonly mislabeled as laetrile, on tumour-associated immunity (TAI) was evaluated by leukocyte adherence inhibition, a suggested in vitro correlate of cellular immunity. A significant (P <0.001) increase in reactivity to malignant prostate was observed with AMG treated PBL from 78% of the patients evaluated. The observed increase in TAI in the presence of AMG may be due to an immunopotentiating effect of this drug. Whether the observed in vitro increase in TAI reflects a similar increase in tumor-host responsiveness in vivo remains to be demonstrated.
|Number of pages
|IRCS Medical Science
|Published - 1981
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology